-

Fitness Equipment Sales Grow by 170% During Coronavirus Lockdown - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the health and wellness industry, "Fitness Equipment Sales Grow by 170% During Coronavirus Lockdown"

In the past few months, most gyms and fitness centers have had to close to prevent the spread of COVID-19. This has created a huge demand for home fitness equipment like exercise bikes, treadmills and rowing machines. Online exercise equipment suppliers have seen a sharp increase in sales as a result.

Demand has been particularly high for smart exercise equipment and companies that offer online fitness programs as consumers try to replicate the gym experience at home. Obe Fitness has seen a big increase in membership as a result of the coronavirus outbreak while sales of the Mirror interactive fitness system have doubled in the last few weeks. Peleton has seen increasing demand for their exercise bike and has responded by offering contact-free delivery of fully assembled units and a free 90 day trial of its workout classes.

To see the full article and a list of related reports on the market, visit "Fitness Equipment Sales Grow by 170% During Coronavirus Lockdown"

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Ireland Buy Now Pay Later Business and Investment Report 2026: Market to Grow by Over 25% to Reach $446.5 Million - Forecasts to 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ireland Buy Now Pay Later Business and Investment Opportunities Databook - 90+ KPIs on BNPL Market Size, End-Use Sectors, Market Share, Product Analysis, Business Model, Demographics - Q1 2026 Update" report has been added to ResearchAndMarkets.com's offering. The BNPL payment market in Ireland is expected to grow by 25.5% on annual basis to reach US$446.5 million in 2026. The buy now pay later market in the country has experienced robust growth during 2022-2025, a...

Indonesia Buy Now Pay Later Business and Investment Report 2026: Market to Grow by 22.2% to Reach $11.15 Billion this Year - Forecasts to 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Indonesia Buy Now Pay Later Business and Investment Opportunities Databook - 90+ KPIs on BNPL Market Size, End-Use Sectors, Market Share, Product Analysis, Business Model, Demographics - Q1 2026 Update" report has been added to ResearchAndMarkets.com's offering. The BNPL payment market in Indonesia is expected to grow by 22.2% on annual basis to reach US$11.15 billion in 2026. The buy now pay later market in the country has experienced robust growth during 2022-202...

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering. The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion. CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT products include Gilead Sciences' Yescarta (axicabtagene ciloleucel) and Novartis's Zolgensma (onasemnogene abeparvovec) which reported sales o...
Back to Newsroom